Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short preoperative gefitinib study in invasive breast cancer
ACTRN12607000013460Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in breast cancer, sponsored by AstraZeneca. Primary endpoints: Molecular alterations in breast cancer tissue after short-term gefitinib exposure and Pharmacokinetic and pharmacodynamic analyses. Started Oct 2003; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12607000013460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000013460.